[144] Ironwood Pharmaceuticals, Inc. - SEC Filing

Rhea-AI Filing Summary

Ironwood Pharmaceuticals Form 144 reports that Tammi Gaskins proposes to sell 1,406 shares of Class A common stock on 08/11/2025 through E Trade (Nasdaq), with an aggregate market value of $1,237.28. The filing states these shares were acquired as 4,000 restricted stock units granted on 08/16/2023.

The notice also discloses a prior sale of 2,563 shares on 05/16/2025 for gross proceeds of $1,486.54. The filer affirms they do not possess undisclosed material adverse information.

Positive

• Transparent disclosure of a proposed Rule 144 sale detailing share count, broker, exchange, and aggregate market value
• Source of shares disclosed: 4,000 shares acquired as restricted stock units on 08/16/2023
• Recent prior sale disclosed: 2,563 shares sold on 05/16/2025 for gross proceeds of $1,486.54
• Seller attestation that they do not possess undisclosed material adverse information

Negative

• Insider liquidity: The filer sold 2,563 shares recently and proposes an additional sale of 1,406 shares, increasing share supply from an insider
• Aggregate values are modest relative to typical institutional transactions, offering limited market signal but indicating insider cashing out of RSU-derived shares

Insights

Securities/Equity Analyst

TL;DR: Routine insider Rule 144 disclosure showing modest planned and recent sales, with shares originating from RSU awards.

The filing documents a proposed sale of 1,406 shares valued at $1,237.28 and a prior sale of 2,563 shares for $1,486.54. The shares to be sold were acquired as 4,000 RSUs on 08/16/2023, which explains the source of the shares and indicates the transactions are linked to equity compensation vesting rather than open-market purchases. This is a compliance disclosure under Rule 144 and does not itself provide operational or financial performance details about the issuer.

Corporate Governance Expert

TL;DR: Disclosure aligns with regulatory requirements; provides transparency on insider liquidity activity.

The notice names the broker (E Trade Securities LLC) and exchange (Nasdaq), and includes an explicit seller representation that no material nonpublic information is known. The provenance of the shares (RSU award) and the specific past sale amounts are disclosed, supporting transparency. As a governance matter, this is a routine insider sale filing rather than an event implying corporate governance change.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Common Stock	E Trade Securities LLC 3 Edison Drive Alpharetta GA 30005	1406	1237.28	161819848	08/11/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Common Stock	08/16/2023	Restricted Stock Unit award granted pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan, subject to vesting requirements	Ironwood Pharmaceuticals, Inc.			4000	08/16/2023	n/a

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Tammi Gaskins c/o Ironwood Pharmaceuticals, Inc. 100 Summer Street, Suite 2300 Boston MA 02110	Class A Common Stock	05/16/2025	2563	1486.54

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Ironwood (IRWD) Form 144 disclose?

The Form 144 shows Tammi Gaskins proposes to sell 1,406 Class A shares (aggregate $1,237.28) and previously sold 2,563 shares on 05/16/2025 for $1,486.54.

What is the origin of the shares being sold in the IRWD Form 144?

The shares to be sold were acquired as 4,000 restricted stock units granted on 08/16/2023 under the issuer's equity incentive plan.

Through which broker and exchange will the proposed IRWD sale occur?

The filing lists E Trade Securities LLC as the broker and Nasdaq as the securities exchange for the proposed sale.

How much were the proceeds from the recent insider sale disclosed in the filing?

The filing reports gross proceeds of $1,486.54 from the sale of 2,563 shares on 05/16/2025.

Does the filer assert knowledge of undisclosed material information in Form 144?

Yes, by signing the notice the person represents they do not know any material adverse information about the issuer that has not been publicly disclosed.